Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04JLF
|
|||
| Drug Name |
1,2-diamino cyclopentane-based derivative 8
|
|||
| Synonyms |
PMID26593218-Compound-30
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H27ClN4O5S
|
|||
| Canonical SMILES |
COC1=C(C(=CC=C1)OC)C(=O)NC2CN(CC2NC3=NC4=C(S3)C=C(C=C4)Cl)C(=O)OCC5=CC=CC=C5
|
|||
| InChI |
1S/C28H27ClN4O5S/c1-36-22-9-6-10-23(37-2)25(22)26(34)30-20-14-33(28(35)38-16-17-7-4-3-5-8-17)15-21(20)32-27-31-19-12-11-18(29)13-24(19)39-27/h3-13,20-21H,14-16H2,1-2H3,(H,30,34)(H,31,32)
|
|||
| InChIKey |
YUAQEWZWSNKNGF-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Orexin receptor type 1 (HCRTR1) | Target Info | Antagonist | [1] |
| Orexin receptor type 2 (HCRTR2) | Target Info | Antagonist | [1] | |
| Target's Patent Info | Orexin receptor type 1 (HCRTR1) | Target's Patent Info | [1] | |
| Orexin receptor type 2 (HCRTR2) | Target's Patent Info | [1] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | G alpha (q) signalling events | |||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.